GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) LT-Debt-to-Total-Asset : 0.00 (As of Dec. 2024)

View and export this data going back to 2000. Start your Free Trial

What is GlaxoSmithKline Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. GlaxoSmithKline Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Dec. 2024 was 0.00.

GlaxoSmithKline Pharmaceuticals's long-term debt to total assets ratio stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

GlaxoSmithKline Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for GlaxoSmithKline Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pharmaceuticals LT-Debt-to-Total-Asset Chart

GlaxoSmithKline Pharmaceuticals Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

GlaxoSmithKline Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

GlaxoSmithKline Pharmaceuticals LT-Debt-to-Total-Asset Calculation

GlaxoSmithKline Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (A: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (A: Mar. 2024 )	/	Total Assets (A: Mar. 2024 )
	=	64.691	/	35566.175
	=	0.00

GlaxoSmithKline Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

LT Debt to Total Assets (Q: Dec. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2024 )	/	Total Assets (Q: Dec. 2024 )
	=	0	/	0
	=

GlaxoSmithKline Pharmaceuticals (NSE:GLAXO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

GlaxoSmithKline Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pharmaceuticals Ltd (NSE:GLAXO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

500660:India

Address

Dr. Annie Besant Road, GSK House, Worli, Mumbai, MH, IND, 400030

Website

https://www.gsk-india.com

GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccines product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives majority of its revenue from India.

GlaxoSmithKline Pharmaceuticals Headlines

No Headlines